December 2016
-
Genoa Pharmaceuticals has announced that studies conducted in conjunction with McMaster University have shown that peak pirfenidone activity can be achieved by lung levels of the drug that remain for only a short period of… Read more . . .
-
Canada has approved GSK’s Incruse Ellipta umeclidinium (UMEC) DPI for the once-daily treatment of COPD, the first approval for its UMEC monotherapy, the company said. GSK received a positive opinion from the EMA’s Committee for… Read more . . .
-
US pharmaceutical company OPKO Health has announced that it will acquire Israeli device company Inspiro Medical whose only product is the Inspiromatic dry powder inhaler. In June 2013, Inspiro announced positive results from a study… Read more . . .
-
Alexza Pharmaceuticals has hired Winston R. Brown, Jr. as VP, Quality, the company has announced. Brown was most recently Global Head, Quality R&D – Pharmaceuticals, Biologics, and Vision Care Devices at Alcon Research. The company… Read more . . .
-
CDMO Molecular Profiles says that it has hired Charles D. Maher as head of US sales in order to “increase awareness and uptake of its pharmaceutical development services in the North American market.” The company’s… Read more . . .
-
Researchers from the University of St. Andrews, the University of Edinburgh, and St. Jude’s Children’s Research Hospital have published data demonstrating that a nasal spray designed to prevent the influenza virus from binding with receptors… Read more . . .
-
Gateway Analytical is inviting anyone attending RDD 2014 in Fajardo, Puerto Rico to a special VIP event on the evening of May 5. Attendees are invited to join Gateway for a sunset sail on a… Read more . . .
-
Inhaled drug developer Prosonix has announced a global licensing agreement with Mylan for its generic versions of GSK’s Flixotide and Flovent fluticasone propionate MDIs for the treatment of asthma. The deal covers two Prosonix MDIs,… Read more . . .
-
Theravance has initiated a dose-ranging Phase 2b study of its TD-4208 long-acting muscarinic antagonist (LAMA), the company announced. The study will compare four different dosages of TD-4208 and placebo, all delivered once daily via jet… Read more . . .
-
Researchers from the Icahn School of Medicine at Mount Sinai have demonstrated that a single 50 mg dose of a ketamine nasal spray could alleviate depressive symptoms in patients with treatment-resistant major depressive disorder within… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland